Michael Palfreyman

Michael Palfreyman

Chief Tech/Sci/R&D Officer at Amorsa Therapeutics, Inc.

Net worth: 334 059 $ as of 2024-04-29

78 year
Health Technology
Consumer Services
Finance

Profile

Michael Gavin Palfreyman is currently a Director at Amakem NV, Chief Operating Officer & Director at Adelia Therapeutics, Inc., and Chief Scientific Officer at Amorsa Therapeutics, Inc. He previously held positions as Chief Scientific Officer at Marc Pharmaceuticals, Inc., VP-Program Management & Product Development at FORUM Pharmaceuticals, Inc., Principal at Psychiatric Genomics, Inc. and Torrey Pines Investment, Inc., and Chief Research & Development Officer at Cybin, Inc. Palfreyman received his doctorate degree from The University of Nottingham in 1970, his undergraduate degree in 1967, and his graduate degree in 1971.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2023-01-11 965,488 ( 0.13% ) 334 059 $ 2024-04-29

Michael Palfreyman active positions

CompaniesPositionStart
Director/Board Member 2011-08-24
Chief Operating Officer -
Chief Tech/Sci/R&D Officer 2013-03-31
All active positions of Michael Palfreyman

Former positions of Michael Palfreyman

CompaniesPositionEnd
CYBIN INC. Chief Tech/Sci/R&D Officer 2023-06-04
Private Equity Investor -
Corporate Officer/Principal -
Corporate Officer/Principal -
Chief Tech/Sci/R&D Officer -
See the detail of Michael Palfreyman's experience

Training of Michael Palfreyman

The University of Nottingham Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Palfreyman's experience

Connections

32

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
CYBIN INC.

Health Technology

Private companies7

Health Technology

Health Technology

Health Technology

Finance

Health Services

Health Technology

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Michael Palfreyman